Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. November 2017 08:12 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference

Pittsburgh, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
04. November 2017 10:45 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse Recovery

Pittsburgh, Nov. 04, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
30. Oktober 2017 08:12 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4th

PITTSBURGH, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
24. Oktober 2017 08:00 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Issuance of Broad Composition of Matter Patent for CT1812, a First-in-Class Alzheimer’s Disease Clinical Candidate

Pittsburgh, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
16. Oktober 2017 08:00 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer’s Candidate, CT1812

Pittsburgh, PA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
20. September 2017 08:00 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics CEO Kenneth I. Moch to Present at Ladenburg Thalmann 2017 Healthcare Conference

PITTSBURGH, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
07. September 2017 10:00 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics CEO Kenneth I. Moch Hosting One-on-Ones at Mizuho Securities CNS Deep Management Day

PITTSBURGH, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
23. August 2017 09:45 ET | Quelle: Cognition Therapeutics, Inc.

Function of Cognition Therapeutics’ Neurological Drug Screening Platform Presented at American Chemical Society National Meeting

PITTSBURGH, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
02. August 2017 08:00 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics Elects Lazard Vice Chairman Stephen Sands to Board of Directors

Pittsburgh, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
31. Juli 2017 08:30 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics CEO Kenneth I. Moch to Present at Canaccord Genuity Annual Growth Conference

Pittsburgh, July 31, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...

Vorherige Seite